404 related articles for article (PubMed ID: 16273359)
1. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
2. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Schiff R; Massarweh S; Shou J; Osborne CK
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
[TBL] [Abstract][Full Text] [Related]
5. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
[TBL] [Abstract][Full Text] [Related]
6. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
7. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Bedard PL; Freedman OC; Howell A; Clemons M
Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
[TBL] [Abstract][Full Text] [Related]
8. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
10. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
Johnston SR
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
[TBL] [Abstract][Full Text] [Related]
11. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
12. New strategies in estrogen receptor-positive breast cancer.
Johnston SR
Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer.
Arpino G; De Angelis C; Giuliano M; Giordano A; Falato C; De Laurentiis M; De Placido S
Oncology; 2009; 77 Suppl 1():23-37. PubMed ID: 20130429
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA; Palmer DH; Moon S; Rea DW
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
[TBL] [Abstract][Full Text] [Related]
15. [Hormone resistance and its modulation in breast cancer].
Kahán Z; Thurzó L
Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
17. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.
Johnston SR
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):889s-99s. PubMed ID: 15701883
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
Johnston SR
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S145-57. PubMed ID: 16113091
[TBL] [Abstract][Full Text] [Related]
19. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.
Lee AV; Cui X; Oesterreich S
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4429s-4435s; discussion 4411s-4412s. PubMed ID: 11916236
[TBL] [Abstract][Full Text] [Related]
20. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
Osborne CK; Schiff R; Arpino G; Lee AS; Hilsenbeck VG
Breast; 2005 Dec; 14(6):458-65. PubMed ID: 16236516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]